Amylyx Pharmaceuticals Presents Trial Design of Global Phase 3 PHOENIX Study of AMX0035 in ALS
Amylyx will present the trial design of its Phase 3 ALS study (A35-004 PHOENIX) of AMX0035 at the European Network to Cure ALS (ENCALS) Meeting 2021.
Trial News & Events
HEALEY ALS Platform Trial Weekly & Monthly Webinar Series
The ALS Team at the Healey Center at Mass General Hospital is committed to an ongoing dialogue about the HEALEY ALS Platform Trial with the entire ALS patient community.
HEALEY ALS Platform Trial Webinar with ALSA
Please join us on Tuesday, September 29th at 5:00 pm EST for an update on the HEALEY ALS Platform Trial and remarks from Kuldip Dave of the ALS Association.
Call for Nominations: 2020 NEALS CRLI
Nominations are now being accepted for the 2020 Virtual Clinical Research Learning Institute!
First Participants Enrolled in the Groundbreaking Trial Led by the Sean M. Healey & AMG Center
As the first ever platform trial for amyotrophic lateral sclerosis (ALS), the HEALEY ALS Platform Trial is testing three proposed drug regimens and will add two more over the next several months.
Apply Now for the 2020 Virtual NEALS Site Investigator Training Seminar
NEALS is pleased to announce a half-day training session for investigators interested in participating in ALS research as a Site Investigator in a multi-center clinical trial.
NEALS ALS GAP Update
The NEALS ALS GAP (ALS Genetic Access Program) provides clinical genetics services to pALS who are under the care of a registered NEALS clinician.
NEALS COVID-19 Statement
As the COVID-19 situation continues to evolve, we know it is of particular concern for the ALS community, both for clinical care and research trials.
NEALS 2020 Principal Investigator Training Seminar
NEALS is pleased to announce a full day training session for investigators interested in developing and conducting multi-center ALS clinical trials as Principal Investigators.
Inaugural Mass General Hospital HEALEY Center International Prize for Innovation in ALS
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS.